RedHill Biopharma Ltd. (RDHL) SEC filings

RDHLNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30

$0.38−0.01 (-1.60%)

Close on Nov 13, 2026Market cap $1.91MP/E –Yield –

SEC filings

40 of RedHill Biopharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 2, 2026	Nov 2, 2026	SEC EDGAR
Current report	6-K	Oct 21, 2026	Oct 21, 2026	SEC EDGAR
Current report	6-K	Oct 19, 2026	Oct 19, 2026	SEC EDGAR
Current report	6-K	Oct 13, 2026	Oct 13, 2026	SEC EDGAR
Current report	6-K	Oct 7, 2026	Oct 7, 2026	SEC EDGAR
Current report	6-K	Sep 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	6-K	Sep 1, 2026	Sep 1, 2026	SEC EDGAR
Current report	6-K	Aug 31, 2026	Aug 31, 2026	SEC EDGAR
Current report	6-K	Aug 7, 2026	Aug 7, 2026	SEC EDGAR
Current report	6-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	6-K	Jul 28, 2026	Jul 28, 2026	SEC EDGAR
Current report	6-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Current report	6-K	Jun 29, 2026	Jun 29, 2026	SEC EDGAR
Current report	6-K	Jun 25, 2026	Jun 25, 2026	SEC EDGAR
Current report	6-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	6-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	6-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	6-K	Jun 18, 2026	Jun 18, 2026	SEC EDGAR
Current report	6-K	Jun 9, 2026	Jun 9, 2026	SEC EDGAR
Current report	6-K	Jun 8, 2026	Jun 8, 2026	SEC EDGAR
Current report	6-K	Jun 2, 2026	Jun 2, 2026	SEC EDGAR
Current report	6-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	6-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Current report	6-K	Apr 27, 2026	Apr 27, 2026	SEC EDGAR
Annual report	20-F	Dec 31, 2025	Apr 27, 2026	SEC EDGAR
Current report	6-K	Apr 22, 2026	Apr 22, 2026	SEC EDGAR
Current report	6-K	Apr 14, 2026	Apr 14, 2026	SEC EDGAR
Current report	6-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	6-K	Feb 25, 2026	Feb 25, 2026	SEC EDGAR
Current report	6-K	Jan 27, 2026	Jan 27, 2026	SEC EDGAR
Current report	6-K	Jan 22, 2026	Jan 22, 2026	SEC EDGAR
Current report	6-K	Jan 5, 2026	Jan 5, 2026	SEC EDGAR
Current report	6-K	Dec 31, 2025	Dec 31, 2025	SEC EDGAR
Current report	6-K	Dec 23, 2025	Dec 23, 2025	SEC EDGAR
Current report	6-K	Dec 15, 2025	Dec 15, 2025	SEC EDGAR
Current report	6-K	Dec 1, 2025	Dec 1, 2025	SEC EDGAR
Current report	6-K	Nov 26, 2025	Nov 26, 2025	SEC EDGAR
Current report	6-K	Nov 4, 2025	Nov 4, 2025	SEC EDGAR
Current report	6-K	Oct 22, 2025	Oct 22, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in RedHill Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Aug 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RDHL.

Compare: RDHL vs XTLB · RDHL vs CANF · RDHL vs LIPO · RDHL vs HIND · RDHL vs RLYB

Revenue growth-96.4% · median -35.6%

Operating margin-2776.9% · median -2853.6%

Company	Revenue	Growth
RLYB	$434.00K	-35.6%
LIPO	$389.78K	-19.4%
RDHL	$286.00K	-96.4%
HIND	$153.10K	-55.6%
XTLB	–	–
CANF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Employees: 13
Held by institutions: 0.0%
Auditor: Kesselman & Kesselman
SEC CIK: 1553846

Advertisement
300 × 250

See a number that looks wrong?